abstract |
In one aspect of the invention, the present invention provides a method of inhibiting the effect of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides a method of treating a subject suffering from a complement-mediated coagulation disorder, such as disseminated intravascular coagulation. The method comprises administering to a subject in need thereof an amount of a MASP-2 inhibitor effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitor inhibits cellular damage associated with MASP-2-mediated alternative complement pathway activation without compromising the classic (C1q-dependent) pathway component of the immune system. In another aspect of the invention, the present invention provides a composition for inhibiting the effect of a lectin-dependent complement activation comprising a therapeutically effective amount of a MASP-2 inhibitor and a pharmaceutically acceptable carrier. |